Bramshill Investments LLC bought a new position in Agilent Technologies, Inc. (NYSE:A - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,760 shares of the medical research company's stock, valued at approximately $505,000.
Other large investors also recently modified their holdings of the company. Wellington Management Group LLP boosted its position in Agilent Technologies by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock valued at $1,250,276,000 after acquiring an additional 59,781 shares in the last quarter. Geode Capital Management LLC boosted its position in Agilent Technologies by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock worth $938,291,000 after purchasing an additional 53,992 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in Agilent Technologies by 0.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company's stock valued at $700,414,000 after buying an additional 47,495 shares during the last quarter. Northern Trust Corp lifted its position in shares of Agilent Technologies by 12.3% during the 4th quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock valued at $563,259,000 after buying an additional 457,713 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Agilent Technologies during the fourth quarter worth about $456,963,000.
Agilent Technologies Price Performance
A stock traded up $2.26 during midday trading on Wednesday, hitting $107.50. 2,139,443 shares of the stock were exchanged, compared to its average volume of 1,885,292. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. The stock has a market cap of $30.65 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 3.05 and a beta of 1.27. The stock's 50-day moving average price is $112.21 and its 200-day moving average price is $129.18. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35.
Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Research analysts predict that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.
Agilent Technologies Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st were issued a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend was Tuesday, April 1st. Agilent Technologies's payout ratio is 22.76%.
Analyst Ratings Changes
Several research analysts recently commented on the company. Jefferies Financial Group dropped their price target on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. TD Cowen boosted their price target on Agilent Technologies to $135.00 and gave the company a "buy" rating in a report on Thursday, April 10th. Barclays cut their target price on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird decreased their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Finally, Wells Fargo & Company decreased their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Agilent Technologies presently has a consensus rating of "Moderate Buy" and a consensus target price of $143.00.
Check Out Our Latest Research Report on Agilent Technologies
Insider Transactions at Agilent Technologies
In other news, Director Daniel K. Podolsky sold 1,819 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the transaction, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. The trade was a 4.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the transaction, the vice president now directly owns 21,786 shares of the company's stock, valued at $2,657,456.28. The trade was a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Featured Stories
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
